Talis Biomedical Corporation TLIS

$ 4.38 3.55%

Quarterly report 2024-Q2
added 08-19-2024

Talis Biomedical Corporation Balance Sheet 2011-2024 | TLIS

Annual Balance Sheet Talis Biomedical Corporation

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-57.1 M	-96.6 M	-219 M	-138 M	-21.6 M	-6.9 M	-	-	-	-	-	-	-
Long Term Debt	16.8 M	29.9 M	12.7 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	2.88 M	3.7 M	1.23 M	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	5 K	42.8 M	60 M	-	-	-	-	-	-	-
Total Current Liabilities	8.77 M	12.7 M	19.1 M	-	-	-	-	-	-	-	-	-	-
Total Liabilities	25.6 M	42.6 M	31.9 M	16 M	46.9 M	63.4 M	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-540 M	-478 M	-365 M	-	-81.8 M	-54.3 M	-	-	-	-	-	-	-
Total Assets	94.7 M	169 M	266 M	198 M	25.7 M	11.4 M	-	-	-	-	-	-	-
Cash and Cash Equivalents	76.7 M	130 M	233 M	173 M	-	-	-	-	-	-	-	-	-
Book Value	69.1 M	127 M	234 M	182 M	-21.1 M	-52 M	-	-	-	-	-	-	-
Total Shareholders Equity	69.1 M	127 M	234 M	-109 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Talis Biomedical Corporation

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	15.9 M	16.3 M	16.8 M	17.2 M	17.6 M	11.7 M	29.9 M	30.3 M	-	12.5 M	12.7 M	13 M	13.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	24.1 M	25.8 M	25.6 M	25.7 M	26.9 M	22.9 M	42.6 M	41.7 M	-	27.8 M	31.9 M	44.3 M	85.8 M	-	16 M	16 M	16 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-562 M	-553 M	-540 M	-527 M	-511 M	-496 M	-478 M	-451 M	-	-398 M	-365 M	-336 M	-298 M	-233 M	-173 M	-173 M	-173 M	-173 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	72.7 M	82.5 M	94.7 M	107 M	123 M	133 M	169 M	194 M	-	231 M	266 M	303 M	380 M	403 M	198 M	198 M	198 M	198 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	59.9 M	70.3 M	76.7 M	88 M	98.2 M	113 M	130 M	144 M	165 M	188 M	233 M	274 M	313 M	348 M	138 M	138 M	138 M	138 M	21.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	48.6 M	56.7 M	69.1 M	81.6 M	96.2 M	110 M	127 M	152 M	-	203 M	234 M	259 M	294 M	403 M	182 M	182 M	182 M	198 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	48.6 M	56.7 M	69.1 M	81.6 M	96.2 M	110 M	127 M	152 M	177 M	203 M	234 M	259 M	294 M	356 M	-109 M	-109 M	-109 M	-109 M	-21.1 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency